Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Areca nut

This article was originally published in The Tan Sheet

Executive Summary

California does not have the legal basis to list areca nut (the seed of Areca catechu) and betel quid as chemicals known to cause cancer, according to comments filed by the American Herbal Products Association Nov. 21. According to AHPA President Michael McGuffin, the state's Office of Environmental Health Hazard Assessment (OEHHA) is using a "labor code shortcut instead of calling a public meeting" where public comment could, and should, be obtained. In addition, AHPA requests that any listing by the state apply only to areca seed (not husk) intended for prolonged chewing. Swallowing the seed in a dietary supplement has no known health consequences, according to AHPA. The International Agency for Research on Cancer recently released findings linking negative health consequences with chewing areca nut and betel quid...
Advertisement

Related Content

AHPA and areca nut

Topics

Advertisement
UsernamePublicRestriction

Register

PS098884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel